Sharlene Mavor — Medical Scientist, Cannabis Advocate & Co-Founder
Meet Sharlene Mavor, a medical scientist specialising in medicinal cannabis research and the Co-Founder and Managing Director of Medicinal Cannabis Research Australia (MCRA) – an organisation dedicated to helping bring medicinal cannabis to those who need it by helping fund those researching the possibilities, educating those who can prescribe it and advocating to those who can make it available to everyone.
Currently involved in two clinical research projects including a clinical trial using cannabidiol (CBD) for methamphetamine addiction. Alongside, coordinating an observational study to evaluate pharmaceutical grade medicinal cannabis oil in patients with chronic pain of musculoskeletal origin. Sharlene is an industry veteran who has advocated for patient access and industry innovation including the build of INDICA HEMP HOUSE — a luxury hempcrete house made of hemp concrete, available for accommodation in Wilyabrup, Western Australia.
So, without further ado, let’s get into it …
1. As a medical scientist, what inspired you to dedicate your expertise to the medicinal cannabis field, and how does your scientific background inform your approach to research and advocacy?
I was convinced that the science stacked up in regard to effective treatment with medicinal cannabis after attending several scientific conferences in the US and Canada in late 2016. I spoke with researchers conducting both pre-clinical and later phase studies, as well as clinicians who had years of experience treating patients with undeniably positive outcomes.
When I came back to Australia, I started hearing local patient stories of success — many shared through our growing online community, and that powered my need to effect change.
My background is in medical laboratory science, particularly immunology, so I was fascinated to learn about the endocannabinoid system and its major role in homeostasis. The way cannabinoid molecules from cannabis interact with our endocannabinoid receptors is scientifically remarkable. Hearing from patients who’d found success where all else had failed was profoundly convincing, and it sparked my empathy. I knew this was the field I wanted to dedicate myself to — educating, researching, and proving the science to sceptical clinicians and policymakers.
2. As Managing Director and Co-Founder of Medicinal Cannabis Research Australia (MCRA), what was the founding vision for the organisation, and how has its role evolved since inception?
The founding vision for Medicinal Cannabis Research Australia was to create the first Australian platform providing foundational education about the endocannabinoid system — not just for prescribers, but for patients and carers too.
We wanted to share credible science alongside patient stories, because their lived experiences are incredibly powerful. We’ve always aimed to bridge the gap between research and real-world application, sharing quality, peer-reviewed clinical studies that support medicinal cannabis use across various conditions.
Another key goal was to advocate for easier patient access by highlighting the red tape clinicians faced when prescribing first became possible in 2017. Since then, we’ve hosted over 30 educational seminars across Australia and pivoted to webinars during COVID, which allowed us to reach international audiences. Many of these sessions are available on our YouTube channel, keeping education freely accessible to all.
3. You’re hosting the Cape to Cape for Cannabis charity walk in April 2026 in Margaret River, Western Australia. What inspired you to turn this walk into a movement, and how will the proceeds support medicinal cannabis research and advocacy?
Our inspiration for Cape to Cape for Cannabis was to create a healthy, integrative way for the Australian medicinal cannabis community to come together — patients, advocates, researchers, and industry. We wanted something that would strengthen connections, inspire collaboration, and encourage everyone to “swim in the same direction” for the benefit of patients.
The walk isn’t just about awareness — it’s about tangible impact, where funds raised will support political advocacy for fairer laws, particularly around driving and workplace testing, as well as help fund both our current and future clinical research projects.
4. In your experience, what are the biggest informational gaps or hurdles currently facing Australian patients trying to access medicinal cannabis treatment?
As someone who’s spent years working in medicinal cannabis education and patient advocacy, I see the same frustrations come up time and time again. While Australia’s framework for medicinal cannabis has come a long way, patients still face major gaps in access, understanding, and support, with the biggest hurdles being:
Understanding Eligibility – The first question most people ask is, “Am I eligible?” — and it’s not an easy one to answer. Current guidelines state that medicinal cannabis is not a first-line treatment for any condition, and that it should only be considered when conventional therapies haven’t worked. But for patients reading about success stories online, that can be confusing and discouraging. Many don’t realise the evidence base varies widely depending on the condition and the product type.
Navigating Access Pathways – Even when patients are eligible, understanding how to actually access medicinal cannabis is another challenge. The process — through the TGA’s Special Access Scheme (SAS-B) or via an Authorised Prescriber — feels bureaucratic and opaque. It’s not something patients can do alone; they need a doctor willing to engage with the paperwork and regulatory steps.
Finding a Prescriber – That leads to one of the biggest barriers of all: finding a prescriber. Many GPs are still hesitant because they feel they lack the training or confidence to prescribe cannabis, or they view the regulatory process as too time-consuming. So patients often end up being referred to specialised clinics or telehealth services, which can add costs or create continuity-of-care issues.
The Cost Burden – Because medicinal cannabis isn’t on the Pharmaceutical Benefits Scheme (PBS), patients pay out of pocket for consultations, prescriptions, and products. For many, that’s a surprise — and for those on fixed incomes or pensions, it can be prohibitive. We see patients having to choose between staying on therapy and paying their bills.
Lack of Clear, Legal Information – Another huge issue is the advertising restrictions around prescription medicines. Companies can’t legally promote cannabis products directly to consumers, which leaves patients searching social media groups for guidance. Unfortunately, that’s where misinformation often spreads. It’s a classic “information vacuum” that makes it hard for patients to get reliable, evidence-based advice.
Product Complexity – Even once prescribed, patients face an overwhelming array of product types — oils, capsules, flowers, tinctures — each with different ratios of CBD and THC. Most products are still considered “unapproved,” and the market changes frequently, so supply and brand continuity can be frustrating for both doctors and patients.
Driving & Workplace Testing – In most states, it’s still illegal to drive with any detectable THC in your system, even if prescribed. Patients are understandably frustrated — they can be completely unimpaired yet still lose their licence. The same goes for workplace drug testing; many employers don’t have clear policies on medicinal cannabis use.
State-by-State Red Tape – Because every state and territory has its own additional regulations on controlled substances, the process can differ depending on where you live. That means delays, extra paperwork, or pharmacies that aren’t familiar with the process — particularly in regional or remote areas.
Changing Regulations & Clinic Models – The rapid rise of telehealth clinics has created both opportunity and concern. Some models offer quick access but limited follow-up, and regulators are rightly tightening standards to ensure proper patient care. It’s crucial we find the right balance between accessibility and accountability.
For most patients, the hardest part isn’t deciding to try medicinal cannabis — it’s finding a prescriber, navigating the system, and affording treatment. Until we streamline processes, expand education, and allow clearer information sharing, these hurdles will persist.
5. Beyond MCRA’s current focus, what emerging areas of medicinal cannabis research excite you most, and where should Australia invest next?
I’m particularly excited about cannabinoid therapies for neurodegenerative diseases such as Parkinson’s, Alzheimer’s, Huntington’s, and dementia. There’s a growing body of anecdotal evidence and patient testimonials suggesting real potential benefits in these areas. I’d love to see more robust clinical research exploring this further.
6. If you could change one law tomorrow to improve the medicinal cannabis landscape for patients, what would it be?
This is easy — for the Australian government at statewide levels to legislate for impairment testing for driving with THC in a driver’s body, rather than the current presence-based testing, which is flawed.
Patients should be able to use their medication and drive if they are not impaired, just as they can with any other prescribed medication.
7. We’d love to hear more about your beautiful Indica Hemp House. What was the vision behind the build, and where can people find out more?
Back in 2018, I attended the Hemp, Health and Innovation Expo, where I first discovered hempcrete during a presentation by Gary Rogers of Hemp Homes Australia. I was captivated by its sustainability, aesthetic beauty, and health benefits.
Having worked in cannabis science, I already understood the plant’s therapeutic potential — but seeing how hemp could revolutionise sustainable construction opened my eyes to another side of this incredible plant.
That moment inspired Indica Hemp House — my dream build. I wanted to create a luxury accommodation retreat that embodied comfort, health, and harmony with nature. Built from hempcrete and designed with eco-conscious detail, Indica is a lakeside escape I’m incredibly proud of.
It’s more than a beautiful home; it’s proof that building differently can feel better, breathe better, and be better for the planet. Guests can learn more or book a stay at www.indica.au.
From scientific research to patient advocacy and sustainable innovation, Sharlene Mavor is helping to shape a more compassionate, evidence-driven future for medicinal cannabis in Australia. Her work continues to bridge the gap between science and society — ensuring that patients, professionals, and policymakers alike understand the true potential of this powerful plant.
For more information, to learn more and to connect with Sharlene & Medicinal Cannabis Research Australia via. the below platforms —
Website: www.mcra.org.au
Instagram: @mcra_au
Facebook: Medicinal Cannabis Research Australia
Learn more about Indica Hemp House: www.indica.au
Learn More
EQWELLIBRIYUM offers end-to-end consulting for organisations navigating the medicinal cannabis market in Australia. With strategic insights and operational frameworks designed to help you thrive, we’re here to help you. Learn more by contacting us today at hello@eqwellibriyum.com.
Stay Updated
Sign up to our mailing list below to stay updated with industry news & insights.
Disclaimer
This article is for educational purposes only and does not constitute legal advice. For guidance specific to your circumstances, you should seek professional legal advice and / or contact the Therapeutic Goods Administration (TGA) and AHPRA.